Clinical data | |
---|---|
Trade names | Afobazole |
Other names | Obenoxazine |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 43.64%, pronounced first-pass effect |
Metabolism | extensive hepatic |
Onset of action | 0.85±0.13 hours |
Elimination half-life | 0.82±0.54 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C15H21N3O2S |
Molar mass | 307.41 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Fabomotizole ( INN; [1] brand name Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions.[ citation needed] Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. [2] [3] [4] [5] [6] Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety. [7]
Experiments of mice have shown antimutagenic and antiteratogenic properties. [8]
Fabomotizole has found little clinical use outside Russia and has not been evaluated by the FDA.
Clinical data | |
---|---|
Trade names | Afobazole |
Other names | Obenoxazine |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 43.64%, pronounced first-pass effect |
Metabolism | extensive hepatic |
Onset of action | 0.85±0.13 hours |
Elimination half-life | 0.82±0.54 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C15H21N3O2S |
Molar mass | 307.41 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Fabomotizole ( INN; [1] brand name Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions.[ citation needed] Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. [2] [3] [4] [5] [6] Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety. [7]
Experiments of mice have shown antimutagenic and antiteratogenic properties. [8]
Fabomotizole has found little clinical use outside Russia and has not been evaluated by the FDA.